Blogroll
Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Patent Opposition Database
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
-
Recent Posts
- TRIPping Up Least Developed Countries on Medicines, Green Tech, and Textbooks?
- Live from the Trans Pacific Partnership: IP Chapter Shows No Sign of Resolution, End of Negotiation in 2013 Highly Unlikely
- TRIPS Exemption Opposed By Obama Administration, Threatening Cost Spike For Drugs In Poorest Nations
- Open Letter to TRIPS Council Chairman on LDC Extension: Alfredo Suescum, Ambassador of Panama to the World Trade Organization (WTO)
- Trans Pacific Partnership Negotiations and the Controversial Issue of Pharmaceutical Test Data Protection
Categories
Category Archives: Generic drug
Political corruption and the ‘free trade’ racket
Source: Aljazeera 29th April,2013 The US-EU free trade pact and TPP are about securing regulatory gains for major corporate interests, writes Baker.
The real cancer killer: rip-off prices for drugs set by ‘profiteering’ Big Pharma giants
Source: The Independent April 29,2013 An influential group of cancer experts has warned that the high prices charged by pharmaceutical companies for cancer drugs are effectively condemning patients to death. The group of more than 100 leading cancer physicians from … Continue reading
Posted in access to medicines, Generic drug, Novartis Case, patent
Tagged Chronic myelogenous leukemia, Imatinib, Novartis
Leave a comment
Doctors Denounce Cancer Drug Prices of $100,000 a Year
Source: New York Times April 25,2013 With the cost of some lifesaving cancer drugs exceeding $100,000 a year, more than 100 influential cancer specialists from around the world have taken the unusual step of banding together in hopes of persuading some leading … Continue reading
Posted in access to medicines, Generic drug, Novartis Case, patent
Tagged Imatinib, Novartis
1 Comment
India must protect access to medicine
Source: Livemint April 22,2013 India needs to safeguard its vital interests in any trade agreement, the way other nations do Is India committed to protecting access to essential medicines for its citizens? Several recent developments have generated national and international debate … Continue reading
South Africa seeks to close drug patent loophole
Source: Healthnexercise April 23, 2013 By Wendell Roelf CAPE TOWN (Reuters) – South Africa plans to overhaul its intellectual property laws to improve access to cheaper medicines by making it harder for pharmaceutical firms to register and roll-over patents for … Continue reading
Tell Members of Congress to Protect Access to Lifesaving Medicines
Source: Doctors Without Borders Doctors Without Borders/Médecins Sans Frontières (MSF) relies on affordable quality generic medicines to treat tuberculosis, malaria, HIV/AIDS, and many more infections for patients in developing countries. But right now the U.S. government is advocating for trade … Continue reading
The Larger Implications of the Novartis-Glivec Judgment
Source: Economic and Political Weekly Vol XLVIII No.17 by Sudip Chaudhari April 27,2013 The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in … Continue reading
Posted in access to medicines, Compulsory Licensing, Generic drug, IP Rights, Novartis Case, patent, patent evergreening, Sec 3 (d), TRIPS, WTO
Tagged Imatinib, Novartis, Patent, Supreme court
Leave a comment
India-EU FTA negotiations have been intensified: Sharma
Source: Moneycontrol April 22,2013 The negotiations between India and the European Union (EU) for a free trade agreement have been “intensified”, Parliament was informed today. “Negotiations across number of tracks including trade in goods, services, investments…government procurement, customs cooperation and … Continue reading
Posted in access to medicines, Generic drug, IP Rights, TRIPS, WTO
Tagged BRIC, BTIA, European Union, Foreign direct investment, India
Leave a comment
